- Profit after tax
- Rs 7,191.1 mn
- EPS
- Rs 22.58 +15.4%
- EPS a year earlier
- Rs 19.57
PSX Pharmaceuticals
GLAXO GlaxoSmithKline Pakistan Limited
Latest results: FY2025 · Dec 2025 Q2 FY2026 · Apr – Jun 2026
FY2025 revenue Rs 65.9 bn (+7.7%), profit Rs 10.0 bn (+53.4%). Dividend paid 2 years in a row.
Last close · 13 Nov 2026
Rs 336.36 ▼ 1.93 (-0.57%)
▼ 14.6% 1 year
- Market cap
- Rs 107.1 bn
- P/E
- 10.3×
- TTM to Jun 2026
- Sector 12.6× · lower
- P/B
- 3.11×
- Quarter to Jun 2026
- Sector 3.11×
- Dividend yield
- 5.1%
- FY2025
- Payers 4.7% · higher
- ROE
- 32.4%
- FY2025
- Sector 21.7% · higher
- EPS
- Rs 32.69
- TTM to Jun 2026
- Book value / share
- Rs 108.12
- Quarter to Jun 2026
Fundamentals
GLAXO at a glance
Revenue · FY2025
Rs 65.9 bn
▲ 7.7% year on year
Profit attributable to shareholders · FY2025
Rs 10.0 bn
▲ 53.4% year on year
EPS – basic (Rs) · FY2025
Rs 31.48
▲ 53.4% year on year
Dividend per share (Rs) · FY2025
Rs 17.00
▲ 70.0% year on year
Net margin · FY2025
15.2%
+4.5 pts year on year
Debt to equity · FY2025
1.1%
+0.5 pts year on year
Price performance
GLAXO returns
Close Rs 336.36
13 Nov 2026
| Period | Return | Rs | vs KSE-100 |
|---|---|---|---|
| MTD Month to date | +5.3% −1.6 pts vs KSE | +16.97 | −1.6 pts KSE +6.9% |
| 3M 3 months | −2.4% −1.2 pts vs KSE | −8.34 | −1.2 pts KSE −1.2% |
| 6M 6 months | −3.5% −9.8 pts vs KSE | −12.28 | −9.8 pts KSE +6.2% |
| YTD Year to date | −13.7% −15.9 pts vs KSE | −53.42 | −15.9 pts KSE +2.2% |
| 1Y 1 year | −14.6% −25.4 pts vs KSE | −57.65 | −25.4 pts KSE +10.7% |
| Long term | |||
| 3Y 3 years | +306.9% +59.7% a year +92.3 pts vs KSE | +253.70 | +92.3 pts KSE +214.7% |
| 5Y 5 years | +131.5% +18.3% a year −157.3 pts vs KSE | +191.07 | −157.3 pts KSE +288.8% |
Price return from the last close before each period; the fiscal year ends 31 December, so year to date is also fiscal year to date. Dividends are not included.
GlaxoSmithKline Pakistan Limited in brief
GlaxoSmithKline Pakistan Limited (GLAXO) reported revenue of Rs 65.9 bn for FY2025 (Jan – Dec 2025), up 7.7% from FY2024.
Profit attributable to shareholders was Rs 10.0 bn (EPS Rs 31.48), up 53.4%, a net margin of 15.2%.
It declared a dividend of Rs 17.00 per share for FY2025.
The balance sheet showed net cash of Rs 8.2 bn.
Return on equity was 32.4%.
Over the last five years revenue grew at a compound 13.4% a year.
At Rs 336.36 (close on 13 Nov 2026) the shares trade at 10.3× earnings (TTM to Jun 2026) and 3.11× book value, with a dividend yield of 5.1%.
Scorecard vs Pharmaceuticals
14 companies- Growth
- Average
- 16.3%
- Profitability
- Strong
- 15.2%
- Financial health
- Strong
- 1.1%
- Valuation
- Strong
- 10.3×
- Dividends
- Above average
- 5.1%
Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.
Corporate
GLAXO announcements & payouts
- Profit after tax
- Rs 4,580.6 mn
- EPS
- Rs 14.38 +9.2%
- EPS a year earlier
- Rs 13.17
Book closure 3 Sep – 4 Sep 2026 · Buy by Mon 31 Aug (est.) for the payout
- Profit after tax
- Rs 2,610.7 mn
- EPS
- Rs 8.20 +22.8%
- EPS a year earlier
- Rs 6.68
- Profit after tax
- Rs 10,025.3 mn
- EPS
- Rs 31.48 +53.4%
- EPS a year earlier
- Rs 20.52
Book closure 23 Apr – 30 Apr 2026 · Buy by Mon 20 Apr (est.) for the payout
Financial highlights
GLAXO financial results
| Rs bn | FY2025 Jan – Dec 2025 | FY2024 Jan – Dec 2024 | FY2023 Jan – Dec 2023 | FY2022 Jan – Dec 2022 | FY2021 Jan – Dec 2021 | FY2020 Jan – Dec 2020 | FY2019 Jan – Dec 2019 | FY2018 Jan – Dec 2018 | FY2017 Jan – Dec 2017 | FY2016 * Jan – Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.9 | 61.2 | 49.7 | 41.8 | 36.7 | 35.1 | 36.6 | 34.0 | 32.8 | 27.6 |
| Gross profit | 24.4 | 15.4 | 3.4 | 7.3 | 9.9 | 7.7 | 7.7 | 8.4 | 8.9 | 7.5 |
| Operating profit | 16.4 | 10.2 | 1.6 | 4.2 | 7.4 | 4.9 | 4.7 | 4.7 | 5.0 | 4.2 |
| Profit after tax | 10.0 | 6.5 | 0.5 | 2.5 | 5.4 | 3.4 | 3.0 | 3.2 | 3.0 | 2.6 |
| Profit attributable to shareholders | 10.0 | 6.5 | 0.5 | 2.5 | 5.4 | 3.4 | 3.0 | 3.3 | 3.0 | 2.8 |
| EPS – basic (Rs) Rs | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 | 10.60 | 9.55 | 10.23 | 9.36 | 8.67 |
| Dividend per share (Rs) Rs | 17.00 | 10.00 | 0.00 | 0.00 | 7.00 | 6.50 | 6.00 | 7.00 | 7.00 | 6.00 |
| Total assets | 50.7 | 45.1 | 38.1 | 35.5 | 30.5 | 26.1 | 23.2 | 22.2 | 21.9 | 21.2 |
| Total equity | 33.7 | 28.3 | 21.7 | 21.1 | 21.0 | 17.5 | 16.1 | 15.4 | 13.5 | 13.5 |
| Total debt | 0.4 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 | — | — | — |
| Net cash from operating activities | 9.2 | 5.6 | 1.9 | (2.3) | 5.4 | 6.5 | 2.7 | 3.1 | 2.3 | 4.4 |
| Capital expenditure | (2.6) | (2.8) | (1.6) | (1.5) | (1.3) | (1.3) | (1.3) | (0.9) | (1.6) | (1.9) |
| Free cash flow (operating cash flow − capex) | 6.6 | 2.8 | 0.2 | (3.9) | 4.1 | 5.2 | 1.4 | 2.3 | 0.7 | 2.6 |
| Rs bn | TTM to Jun 2026 | Q2 FY2026 Apr – Jun 2026 | Q1 FY2026 Jan – Mar 2026 | Q4 FY2025 Oct – Dec 2025 | Q3 FY2025 Jul – Sep 2025 | Q2 FY2025 Apr – Jun 2025 | Q1 FY2025 Jan – Mar 2025 | Q4 FY2024 Oct – Dec 2024 | Q3 FY2024 Jul – Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.1 | 14.5 | 17.0 | 21.4 | 14.2 | 14.7 | 15.6 | 17.6 | 14.7 |
| Gross profit | 25.6 | 5.5 | 6.4 | 8.5 | 5.2 | 5.4 | 5.3 | 5.8 | 4.0 |
| Operating profit | 16.8 | 3.2 | 4.3 | 6.1 | 3.2 | 3.4 | 3.6 | 4.7 | 2.7 |
| Profit after tax | 10.4 | 2.0 | 2.6 | 3.8 | 2.0 | 2.1 | 2.1 | 3.0 | 1.9 |
| Profit attributable to shareholders | 10.4 | 2.0 | 2.6 | 3.8 | 2.0 | 2.1 | 2.1 | 3.0 | 1.9 |
| EPS – basic (Rs) Rs | 32.69 | 6.19 | 8.20 | 11.91 | 6.40 | 6.50 | 6.68 | 9.27 | 6.05 |
| Dividend per share (Rs) Rs | 19.00 | 7.00 | 0.00 | 12.00 | 0.00 | 5.00 | 0.00 | 10.00 | 0.00 |
| Total assets | 52.6 | 52.6 | 54.0 | 50.7 | 51.0 | 48.1 | 48.8 | 45.1 | 47.3 |
| Total equity | 34.4 | 34.4 | 36.3 | 33.7 | 29.7 | 29.3 | 30.4 | 28.3 | 25.3 |
| Total debt | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 |
| Net cash from operating activities | 9.5 | 2.6 | 1.7 | 2.6 | 2.6 | 3.9 | 0.1 | 0.4 | 2.7 |
| Capital expenditure | (2.4) | (0.4) | (0.3) | (1.0) | (0.6) | (0.5) | (0.5) | (1.2) | (0.5) |
| Free cash flow (operating cash flow − capex) | 7.1 | 2.2 | 1.3 | 1.6 | 2.0 | 3.4 | (0.4) | (0.8) | 2.2 |
Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.
GLAXO charts
Valuation
GLAXO valuation at today's price
- Price to earnings (P/E)
- 10.3×
- EPS Rs 32.69 (TTM to Jun 2026)
- Price to book (P/B)
- 3.11×
- Book value Rs 108.12 (Quarter to Jun 2026)
- Dividend yield
- 5.1%
- DPS Rs 17.00 (FY2025)
- Earnings yield
- 9.7%
- EPS ÷ price
At the closing price of Rs 336.36 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.
Sector peers
GLAXO vs Pharmaceuticals companies
| Company | Market cap | P/E | P/B | Yield | ROE | 3-yr growth |
|---|---|---|---|---|---|---|
| GLAXO | Rs 107.1 bn | 10.3× | 3.11× | 5.1% | 32.4% | 16.3% |
| ABOT | Rs 97.9 bn | 11.4× | 3.05× | 4.0% | 28.8% | 15.2% |
| HALEON | Rs 81.6 bn | 12.4× | 5.02× | 4.3% | 47.6% | 16.2% |
| HINOON | Rs 50.8 bn | 12.8× | 3.95× | 5.2% | 32.3% | 20.5% |
| AGP | Rs 43.8 bn | 11.7× | 2.92× | 5.1% | 25.9% | 26.0% |
| HPL | Rs 38.5 bn | 10.3× | 4.50× | 6.0% | 38.6% | 18.6% |
| FEROZ | Rs 15.8 bn | 16.1× | 1.19× | 1.5% | 7.6% | 27.9% |
| CPHL | Rs 14.5 bn | 18.3× | 1.34× | 0.0% | 7.3% | 4.3% |
| MACTER | Rs 12.0 bn | 17.7× | 2.87× | 0.0% | 17.4% | 20.7% |
Analyses & signals 0
Win rate — · 0 closed signals · average return —
No analyses published for GLAXO yet.
GLAXO: frequently asked questions
What is GLAXO's EPS?
GlaxoSmithKline Pakistan Limited reported basic earnings per share of Rs 31.48 for FY2025 (Jan – Dec 2025). Over the trailing twelve months (TTM to Jun 2026) EPS was Rs 32.69.
What is GLAXO's P/E ratio?
At the closing price of Rs 336.36 on 13 Nov 2026, GLAXO trades at a P/E of 10.3× based on EPS of Rs 32.69 (TTM to Jun 2026).
Does GLAXO pay dividends?
Yes. GlaxoSmithKline Pakistan Limited declared a dividend of Rs 17.00 per share for FY2025. It has paid a dividend in each of the last 2 years. At Rs 336.36 that is a dividend yield of 5.1%.
What was GLAXO's revenue and profit in FY2025?
GlaxoSmithKline Pakistan Limited reported revenue of Rs 65.9 bn and profit attributable to shareholders of Rs 10.0 bn for FY2025 (Jan – Dec 2025).
What is GLAXO's book value per share?
GlaxoSmithKline Pakistan Limited's book value per share was Rs 105.74 at the end of FY2025. The shares trade at 3.11× book value.
How has GLAXO's share price performed?
GLAXO's share price is down 13.7% year to date (KSE-100: +2.2%), down 14.6% over one year (KSE-100: +10.7%) and up 131.5% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.
Information only, not investment advice.